| 公告主旨 |
[演講] 12/14 林家齊 老師 主講:橋接癌症基因體和藥物開發 / Bridging Cancer Genomics and Drug Development |
| 公告內容 |
臺大基蛋所Medical Genetics & Genomics Monthly Seminar演講邀請
[講題]:橋接癌症基因體和藥物開發 / Bridging Cancer Genomics and Drug Development
[講者]:林家齊 教授(台大醫學院臨醫所教授兼所長&台大醫院腫瘤醫學部主治醫師)
CV:https://www.mc.ntu.edu.tw/medgenpro/News.action?q_type=-1&q_itemCode=12551
[時間]:2026/12/14 (星期一) 上午11:20-12:10
[Hybrid Meeting]: *地點: 醫學院基醫大樓202講堂 *Webex: https://ntumc.webex.com/ntumc-tc/j.php?MTID=m1d9a9425eb0d0cd6a4e4a01b3bd6e3e4
[摘要]:
Cancer genomics transformed oncology drug development from a "one-size-fits-all" approach into precision medicine, matching specific molecular alterations in cancers to targeted therapies. Technologies like next-generation sequencing and liquid biopsies decode hundreds of tumor genes simultaneously to pinpoint driver mutations. Profiling has expanded from single-gene binaries into multi-omics (transcriptomics, proteomics, and spatial genomics) and quantitative thresholds (e.g. HER2-low breast cancer or homologous recombination deficiency). Drug development increasingly co-develops diagnostic tests (companion diagnostics) alongside therapeutics (e.g. vemurafenib with BRAF mutation, gefitinib with EGFR mutation, crizotinib with ALK fusion) to select patients most likely to respond or avoid toxic inefficacy. Traditional histology-based trials are complemented by basket trials, umbrella trials (e.g. Lung-MAP), and master protocols (e.g., NCI-MATCH). Key challenges include tumor heterogeneity and drug resistance, health equity and access to genotype-matched therapies, regulatory hurdles.
歡迎踴躍參加!
◎每月精彩演講已放到網路上囉,歡迎大家一起來重溫精彩內容!http://speech.ntu.edu.tw/ntuspeech/Cate/index/id-3
◎歡迎加入演講FB社團,掌握最新演講消息:Medical Genetics & Genomics Monthly Seminar https://www.facebook.com/groups/1109733759041652/
臺大基蛋所 與 臺大醫院基因醫學部 敬邀
|
|
| 附件名稱 |
檔案大小 |
| 演講海報 |
240505 Bytes |
|